A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev)

Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation

“…The R-GemOX (rituximab, gemcitabine, and oxaliplatin) combination is one of the most widely used since the publication of a prospective study showing its efficacy and acceptable tolerability [8,9]. However, since this publication, very few data have confirmed these results in patients with R/R DLBCL [10][11][12].…”